Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate United Therapeutics Corporation before investing.

In this article, we go over a few key elements for understanding United Therapeutics Corporation’s stock price such as:

• United Therapeutics Corporation’s current stock price and volume
• Why United Therapeutics Corporation’s stock price changed recently
• Upgrades and downgrades for UTHR from analysts
• UTHR’s stock price momentum as measured by its relative strength

About United Therapeutics Corporation (UTHR)

Before we jump into United Therapeutics Corporation’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Want to learn more about United Therapeutics Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about United Therapeutics Corporation.

United Therapeutics Corporation’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, United Therapeutics Corporation’s stock price was $517.710.

United Therapeutics Corporation is down 1.54% from its previous closing price of $525.820.

During the last market session, United Therapeutics Corporation’s stock traded between $514.340 and $525.840. Currently, there are approximately 43.50 million shares outstanding for United Therapeutics Corporation.

United Therapeutics Corporation’s price-earnings (P/E) ratio is currently at 19.4, which is high compared to the Biotechnology industry median of 18.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

United Therapeutics Corporation Stock Price History

United Therapeutics Corporation’s (UTHR) price is currently down 4.45% so far this month.

During the month of July, United Therapeutics Corporation’s stock price has reached a high of $563.700 and a low of $514.340.

Over the last year, United Therapeutics Corporation has hit prices as high as $609.350 and as low as $272.120. Year to date, United Therapeutics Corporation’s stock is up 6.25%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused United Therapeutics Corporation Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were 0 analysts who downgraded United Therapeutics Corporation’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate United Therapeutics Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on United Therapeutics Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

United Therapeutics Corporation’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about United Therapeutics Corporation (UTHR) by visiting AAII Stock Evaluator.

Relative Price Strength of United Therapeutics Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, United Therapeutics Corporation has a weighted four-quarter relative price strength of 8.76%, which translates to a Momentum Score of 79 and is considered to be Strong.

Want to learn more about how United Therapeutics Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

United Therapeutics Corporation Stock Price: Bottom Line

As of July 31, 2026, United Therapeutics Corporation’s stock price is $517.710, which is down 1.54% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like United Therapeutics Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.